
Alan YeungGlasgow Caledonian University | GCU · Department of Life Sciences
Alan Yeung
PhD in Statistics
About
21
Publications
1,650
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
224
Citations
Citations since 2017
Introduction
Alan Yeung currently works in the BBV/STI team at Public Health Scotland and as a research fellow at Glasgow Caledonian University. Alan does research in Statistics, Hepatology and Infectious Diseases - particularly BBV/STI.
Education
October 2009 - August 2016
October 2005 - July 2009
Publications
Publications (21)
Background:
Take-home naloxone (THN) programmes have been associated with reductions in opioid-related mortality. In response to high rates of drug-related deaths in Scotland, the Scottish Government commissioned the 'How to save a life' (HTSAL) mass media campaign to: (1) increase awareness of drug-related deaths and how to respond to an overdose...
Objectives
To quantify mortality rates for patients successfully treated for hepatitis C in the era of interferon-free, direct acting antivirals and compare these rates with those of the general population.
Design
Population based cohort study.
Setting
British Columbia, Scotland, and England (England cohort consists of patients with cirrhosis onl...
Background:
Drug-related death (DRD) rate in Scotland, UK, has increased rapidly to one of the highest in the world. Our aim was to examine the extent to which opioid-agonist therapy (OAT) in Scotland is protective against drug-related mortality and how this effect has varied over time.
Methods:
We included individuals in Scotland with opioid us...
Background:
Risk scores estimating a patient's probability of a hepatocellular carcinoma (HCC) diagnosis are abundant, but are difficult to interpret in isolation. Here, we compared the predicted HCC probability for individuals with cirrhosis and cured hepatitis C to the general population (GP).
Methods:
All patients with cirrhosis achieving sus...
Background and Aims
Existing models predicting hepatocellular carcinoma (HCC) occurrence do not account for competing risk events and, thus, may overestimate the probability of HCC. Our goal was to quantify this bias for patients with cirrhosis and cured hepatitis C.
Methods
We analyzed a nationwide cohort of patients with cirrhosis and cured hepa...
Background
COVID-19 has likely affected the delivery of interventions to prevent blood-borne viruses (BBVs) among people who inject drugs (PWID). We examined the impact of the first wave of COVID-19 in Scotland on: 1) needle and syringe provision (NSP), 2) opioid agonist therapy (OAT) and 3) BBV testing.
Methods
An interrupted time series study de...
Background & Aims
The impact of interferon (IFN)-free therapies on the epidemiology of hepatitis C virus (HCV) related hepatocellular carcinoma (HCC) is not well understood at a population level. Our goal was to bridge this evidence gap.
Methods
This study included all patients in Scotland with chronic HCV and a diagnosis of cirrhosis during 1999-...
Background & aims:
Scale-up of highly-effective direct-acting antivirals (DAAs) for hepatitis C virus (HCV) among people who inject drugs (PWID) in Scotland has led to a reduction in prevalence of viraemia in this population. However, the extent of reinfection among those treated with DAAs remains uncertain. We estimated HCV reinfection rates amon...
BACKGROUND
Hepatocellular carcinoma (HCC) prediction models can inform clinical decisions about HCC screening provided their predictions are robust. We conducted an external validation of six HCC prediction models for UK patients with cirrhosis and a hepatitis C virus (HCV) virological cure.
METHODS
Cirrhosis patients with cured HCV were identifie...
Background
Drug-related deaths globally are increasing year on year, with the largest proportion of these being opioid-related. The opioid antagonist naloxone distributed for take-home use (‘Take-Home Naloxone (THN)’) has been championed as one method of tackling this public health crisis, however to be effective it must be available at an opioid o...
Background and aims:
There has been little empirical evidence to show the 'real world' impact of scaling-up direct-acting antiviral (DAA) treatment among people who inject drugs (PWID) on hepatitis C virus (HCV) viraemia at a population level. We aimed to assess the population impact of rapid DAA scale-up to PWID delivered through community servic...
Objectives
To review characteristics of individuals newly diagnosed with HIV following implementation of a national pre-exposure prophylaxis (PrEP) programme (comprehensive PrEP services, delivered in sexual health clinics) to inform future delivery and broader HIV prevention strategies.
Methods
We extracted data from national HIV databases (July...
Faced with the 2020 SARS-CoV2 epidemic, public health officials have been seeking models that could be used to predict not only the number of new cases but also the levels of hospitalisation, critical care and deaths. In this paper we present a stochastic compartmental model capable of real-time monitoring and forecasting of the pandemic incorporat...
Objective:
The aim of this study was to evaluate Scotland's national HIV preexposure prophylaxis (PrEP) programme in relation to PrEP uptake and associated population-level impact on HIV incidence among MSM.
Design:
A retrospective cohort study within real-world implementation.
Methods:
Comparison of HIV diagnoses from national surveillance da...
Objective
Population-based studies demonstrating the clinical impact of interferon-free direct-acting antiviral (DAA) therapies are lacking. We examined the impact of the introduction of DAAs on HCV-related decompensated cirrhosis (DC) through analysis of population-based data from Scotland.
Design
Through analysis of national surveillance data (i...
Introduction
Hepatitis C virus (HCV) is the second largest contributor to liver disease in the UK, with injecting drug use as the main risk factor among the estimated 200 000 people currently infected. Despite effective prevention interventions, chronic HCV prevalence remains around 40% among people who inject drugs (PWID). New direct-acting antivi...
Background:
Novel Psychoactive Substance (NPS) use has increased in recent years and generated significant concern within public health. People who inject drugs (PWID) are at increased risk of blood borne viruses, in particular Hepatitis C virus (HCV). However, little is known about the extent of NPS injecting at a national level and its associati...
Background and aims:
In Scotland, Hepatitis B virus (HBV) vaccination for all prisoners was introduced in 1999; here, we examine the impact of this programme among people who inject drugs (PWID) in the community. This study aimed to compare rates of HBV vaccine uptake before and after implementation of the prison programme and to estimate the dete...
Background and aims:
In April 2015, the UK government enacted a temporary class drug order (TCDO) on ethylphenidate in response to reported harms associated with its use, in particular an outbreak of infections among people who inject drugs (PWID) in Lothian, Scotland. This study assesses the effect that the TCDO had on reducing the most common in...